A Phase 1, 2-Part, Multicenter, Open-label, 3-Arm Study to Determine the effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Doses of Caffeine, Dextromethorphan, Flurbiprofen, Midazolam, Omeprazole, Digoxin, Rosuvastatin, and Pioglitazone in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring an Isocitrate Dehydrogenase 2 Mutation